Jianmin Pharmaceutical Group Co.,Ltd.

SHSE:600976 Stock Report

Market Cap: CN¥6.4b

Jianmin Pharmaceutical GroupLtd Past Earnings Performance

Past criteria checks 1/6

Jianmin Pharmaceutical GroupLtd has been growing earnings at an average annual rate of 32.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13.9% per year. Jianmin Pharmaceutical GroupLtd's return on equity is 17.9%, and it has net margins of 10.8%.

Key information

32.1%

Earnings growth rate

32.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate13.9%
Return on equity17.9%
Net Margin10.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Apr 26
We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Recent updates

Potential Upside For Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) Not Without Risk

Nov 10
Potential Upside For Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) Not Without Risk

If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Sep 25
If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

Aug 25
Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

Jul 12
The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jun 30
We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

May 21
We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Apr 26
We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Revenue & Expenses Breakdown

How Jianmin Pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600976 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,9774281,40582
30 Jun 244,0615081,44879
31 Mar 244,1705211,44179
31 Dec 234,2135211,51874
30 Sep 233,9485081,42578
30 Jun 233,9654721,40978
31 Mar 233,7364191,31174
31 Dec 223,6414081,21473
30 Sep 223,5033631,19274
30 Jun 223,3443261,12667
31 Mar 223,3763241,12562
31 Dec 213,2993051,13453
30 Sep 213,4562791,13539
30 Jun 213,2212581,08338
31 Mar 212,8571991,05641
01 Jan 212,45614889137
30 Sep 202,01314481245
30 Jun 202,1549380142
31 Mar 202,1648378036
01 Jan 202,2399179141
30 Sep 192,4028274528
30 Jun 192,1998069630
31 Mar 192,1837966829
01 Jan 192,1618167126
30 Sep 182,1889174027
30 Jun 182,31110072135
31 Mar 182,62510268330
31 Dec 172,7129164724
30 Sep 172,7488160415
30 Jun 172,677715790
31 Mar 172,315595430
31 Dec 162,364655090
30 Sep 162,495694560
30 Jun 162,430804480
31 Mar 162,449834240
31 Dec 152,281864040
30 Sep 151,953863840
30 Jun 151,8601023240
31 Mar 151,7481143170
31 Dec 141,7531163280
30 Sep 141,6851183140
30 Jun 141,7161083320
31 Mar 141,867983390
31 Dec 131,992963360

Quality Earnings: 600976 has a high level of non-cash earnings.

Growing Profit Margin: 600976's current net profit margins (10.8%) are lower than last year (12.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600976's earnings have grown significantly by 32.1% per year over the past 5 years.

Accelerating Growth: 600976's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600976 had negative earnings growth (-15.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 600976's Return on Equity (17.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:30
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jianmin Pharmaceutical Group Co.,Ltd. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Jing QiangChina International Capital Corporation Limited
Xiaoyu QianHuatai United Securities Co., Ltd.